Cargando…

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?

Prostate Specific Membrane Antigen (PSMA) is strongly expressed in prostate cancer. Recently a number of low-molecular-weight inhibitors have demonstrated excellent PSMA targeting activity for both imaging as well as Lutecium-177 radiotherapy in human trials. The paper by Choy et al raises the quest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Steve S., Heston, Warren D.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479280/ https://www.ncbi.nlm.nih.gov/pubmed/28638479 http://dx.doi.org/10.7150/thno.20284

Ejemplares similares

GCP III is not the “off-target” for urea-based PSMA ligands
por: Lee, Zhenghong, et al.
Publicado: (2023)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer
por: Ren, Ya’nan, et al.
Publicado: (2022)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer
por: Derks, Yvonne H.W., et al.
Publicado: (2021)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

PSMA Ligand Conjugated PCL-PEG Polymeric Micelles Targeted to Prostate Cancer Cells
por: Jin, Jian, et al.
Publicado: (2014)

Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
por: Zhou, Haoxi, et al.
Publicado: (2021)

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
por: Derks, Yvonne H. W., et al.
Publicado: (2023)

The effect of eating on the uptake of PSMA ligands in the salivary glands
por: Mohan, V., et al.
Publicado: (2021)

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
por: Lee, Sung Chang, et al.
Publicado: (2021)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

In situ Generated (212)Pb-PSMA Ligand in a (224)Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-Positive Cells
por: Stenberg, Vilde Y., et al.
Publicado: (2020)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

Determination of pharmacokinetics and tissue distribution of a novel lutetium-labeled PSMA-targeted ligand, (177)Lu-DOTA-PSMA-GUL, in rats by using LC–MS/MS
por: Song, Chang Ho, et al.
Publicado: (2022)

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
por: Sjögreen Gleisner, Katarina, et al.
Publicado: (2022)

Optimized Therapeutic (177)Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with (177)Lu-PSMA and Combined (225)Ac- and (177)Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
por: Langbein, Thomas, et al.
Publicado: (2022)

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine
por: Palameta, Soledad, et al.
Publicado: (2022)

Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting
por: Lim, Jongdoo, et al.
Publicado: (2019)

Preclinical Evaluation of a New Series of Albumin-Binding (177)Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
por: Boinapally, Srikanth, et al.
Publicado: (2023)

Strain-Promoted Azide–Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer
por: Derks, Yvonne H. W., et al.
Publicado: (2021)

Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression
por: Yin, Lihong, et al.
Publicado: (2011)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC
por: Kramer, Vasko, et al.
Publicado: (2020)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

PSMA-targeted therapy for non-prostate cancers
por: Wang, Jarey H., et al.
Publicado: (2023)

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA)
por: Shen, Duanwen, et al.
Publicado: (2013)

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
por: Gaertner, Florian C., et al.
Publicado: (2017)

A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022)

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for (177)Lu-Labeled PSMA-Targeting Peptides
por: Kletting, Peter, et al.
Publicado: (2016)

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
por: Begum, Nusrat J., et al.
Publicado: (2019)

Development of an Albumin-Based PSMA Probe With Prolonged Half-Life
por: Liu, Teli, et al.
Publicado: (2020)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dcdg27tds2fshklsj05jmnh5ui